Novartis continues to ‘reimagine’ itself, as Alcon spin-off completed
The new standalone company is worth up to 28 billion Swiss francs.
Read More
Tag: Alcon
Novartis to spin off eye unit Alcon
Novartis has announced plans to spin off its eye-care unit Alcon into a standalone entity.
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
